Corrigendum

Corrigendum to "Interleukin-9 Deletion Relieves Vascular Dysfunction and Decreases Blood Pressure via the STAT3 Pathway in Angiotensin II-Treated Mice"

Yunzhao Yang, Shaoqun Tang, Chunchun Zhai, Xin Zeng, Qingjian Liu, Cheng Xu, and Hexiang Chen

Department of Anesthesiology, Wuhan University, Renmin Hospital, Wuhan, 430060 Hubei Province, China

Correspondence should be addressed to Hexiang Chen; chx163yx@163.com

Received 23 October 2020; Accepted 23 October 2020; Published 9 November 2020

Copyright © 2020 Yunzhao Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled "Interleukin-9 Deletion Relieves Vascular Dysfunction and Decreases Blood Pressure via the STAT3 Pathway in Angiotensin II-Treated Mice" [1], the authors apologize that a blot of P-STAT3 which did not belong to this study was mistakenly used in (Figure 6(c)). The statistical results of P-STAT3 protein expression were correct, and the corrected (Figure 6(c)) is shown below.



FIGURE 6: Effects of S31-201 on blood pressure, inflammation, and phenotypic transformation of smooth muscle. (a, b) Blood pressure was determined using the tail-cuff method and the Millar Pressure Volume System; N = 10 in each group. (c) The STAT3 phosphorylation in each group was measured. (d) The vascular function for the four groups was detected. (e) Serum cytokine levels were measured using ELISA kits. (f) Aortic mRNA expression of cytokines was analyzed by RT-PCR. N = 5 in each group; *p < 0.05 vs. the IL-9-/- Ang II+DMSO group.

References

 Y. Yang, S. Tang, C. Zhai et al., "Interleukin-9 deletion relieves vascular dysfunction and decreases blood pressure via the STAT3 pathway in angiotensin II-treated mice," *Mediators of Inflammation*, vol. 2020, Article ID 5741047, 12 pages, 2020.